Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells (Q45392719)

14 December 2017

title

Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells (English)

1 reference

14 December 2017

6

1 reference

14 December 2017

Adelheid Wöhrer

2

0 references

Andreas von Deimling

8

object named as

Andreas von Deimling

1 reference

14 December 2017

9

David Capper

1 reference

14 December 2017

4

Jens Schittenhelm

1 reference

14 December 2017

Christian Koelsche

1

1 reference

14 December 2017

Astrid Jeibmann

3

1 reference

14 December 2017

Genevieve Schindler

5

1 reference

14 December 2017

Felix Lasitschka

7

1 reference

14 December 2017

publication date

24 February 2013

1 reference

14 December 2017

published in

Acta Neuropathologica

1 reference

14 December 2017

volume

125

1 reference

14 December 2017

issue

6

1 reference

14 December 2017

page(s)

891-900

1 reference

https://scigraph.springernature.com/pub.10.1007/s00401-013-1100-2

14 December 2017

exact match

0 references

cites work

Immunogenicity of constitutively active V599EBRaf

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Mutational analysis of TSC1 and TSC2 genes in gangliogliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Detection of the BRAF V600E mutation in serous ovarian tumors: a comparative analysis of immunohistochemistry with a mutation-specific monoclonal antibody and allele-specific PCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Clinical and molecular characteristics of malignant transformation of low-grade glioma in children

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Utilization of a MAB for BRAF(V600E) detection in papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Immunohistochemical testing of BRAF V600E status in 1,120 tumor tissue samples of patients with brain metastases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Detection of BRAF p.V600E mutations in melanomas: comparison of four methods argues for sequential use of immunohistochemistry and pyrosequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Malignant ganglioglioma: case report and review of literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

BRAF V600E mutations are common in pleomorphic xanthoastrocytoma: diagnostic and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Unlocking the code of 14-3-3.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Functional characterization of a BRAF insertion mutant associated with pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Activation of the ERK/MAPK pathway: a signature genetic defect in posterior fossa pilocytic astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Potential tumor suppressive pathway involving DUSP6/MKP-3 in pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

BRAF-KIAA1549 fusion transcripts are less frequent in pilocytic astrocytomas diagnosed in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Comprehensive characterization of genomic aberrations in gangliogliomas by CGH, array-based CGH and interphase FISH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Duplication of 7q34 is specific to juvenile pilocytic astrocytomas and a hallmark of cerebellar and optic pathway tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Genetic aberrations leading to MAPK pathway activation mediate oncogene-induced senescence in sporadic pilocytic astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Mutation analysis of the Ras pathway genes NRAS, HRAS, KRAS and BRAF in glioblastomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Immunohistochemical detection of the BRAF V600E-mutated protein in papillary thyroid carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

BRAF mutations are associated with distinctive clinical, pathological and molecular features of colorectal cancer independently of microsatellite instability status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

The ras/mitogen-activated protein kinase pathway inhibitor and likely tumor suppressor proteins, sprouty 1 and sprouty 2 are deregulated in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

The 2007 WHO classification of tumours of the central nervous system

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Profiling critical cancer gene mutations in clinical tumor samples

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

BRAF activation induces transformation and then senescence in human neural stem cells: a pilocytic astrocytoma model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Comparative histological, histochemical, immunohistochemical and biochemical studies on oestrogen receptors, lectin receptors, and Barr bodies in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

BRAFV600E mutant protein is expressed in cells of variable maturation in Langerhans cell histiocytosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Oncogenic BRAF mutation with CDKN2A inactivation is characteristic of a subset of pediatric malignant astrocytomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

Pediatric primary anaplastic ganglioglioma: a case report and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

SPRY2 is an inhibitor of the ras/extracellular signal-regulated kinase pathway in melanocytes and melanoma cells with wild-type BRAF but not with the V599E mutant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00401-013-1100-2

10.1007/S00401-013-1100-2

21 January 2018

Identifiers

DOI

1 reference

Dimensions Publication ID

14 December 2017

1005778684

0 references

1 reference